Herishanu Yair, Perry Chava, Braunstein Rony, Metser Ur, Goor Odelia, Rogowski Ori, Berliner Shlomo, Polliack Aaron, Naparstek Elizabeth
Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Eur J Haematol. 2007 Aug;79(2):150-4. doi: 10.1111/j.1600-0609.2007.00894.x.
In the light of an emerging role for early-mid treatment 18 F-deoxyfluoroglucose positron emission tomography (FDG-PET) as an important prognostic indicator in aggressive non-Hodgkin's lymphoma (NHL) , we attempted to determine whether a simple parameter, such as the early-mid treatment CRP (C-reactive protein) level, could also be utilized as a significant prognostic factor in aggressive NHL.
Serum CRP levels were monitored in 55 patients with aggressive NHL. The lowest value of the early mid-term CRP levels recorded was compared with the interim PET-CT results, as well as with the clinical course and eventual outcome.
During chemotherapy, the lowest value of early-mid treatment CRP levels significantly predicted the results of the interim FDG-PET (P = 0.04 with an odds ratio of 1.13). Patients who did not achieve an early-mid treatment CRP level of <5 mg/L, had a shorter time to disease progression or relapse (P = 0.001) as well as a reduced overall survival (OS) (P = 0.016).
The early-mid treatment serum CRP level is a prognostic factor in aggressive NHL. Patients who do not achieve an early-mid treatment level of <5 mg/L have quicker disease progression or earlier relapse and also appear to have an inferior OS.
鉴于治疗中早期18F-脱氧氟葡萄糖正电子发射断层扫描（FDG-PET）在侵袭性非霍奇金淋巴瘤（NHL）中作为重要预后指标的作用逐渐显现，我们试图确定一个简单参数，如治疗中早期C反应蛋白（CRP）水平，是否也可作为侵袭性NHL的重要预后因素。
对55例侵袭性NHL患者的血清CRP水平进行监测。将记录的治疗中早期CRP水平的最低值与中期PET-CT结果、临床病程及最终结局进行比较。
化疗期间，治疗中早期CRP水平的最低值可显著预测中期FDG-PET结果（P = 0.04，优势比为1.13）。治疗中早期CRP水平未达到<5 mg/L的患者，疾病进展或复发时间较短（P = 0.001），总生存期（OS）也较短（P = 0.016）。
治疗中早期血清CRP水平是侵袭性NHL的一个预后因素。治疗中早期水平未达到<5 mg/L的患者疾病进展更快或复发更早，且总生存期似乎更短。
